EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line therapy for patients with non-small-cell lung cancer (NSCLC) harboring EGFR-activating mutations [1,2,3].